GlassScriptPhysician profile
Carolyn J Bogan
NPI 1770995649
$2,504.20
in general payments reported to CMS, 2019-2025
14 companies · $950 in 2025
The $950 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $460 · 2023: $272 · 2024: $823 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,044.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $486.95 | 2022-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $457.99 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $424.78 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $278.22 | 2024-2025 | Mounjaro, Zepbound |
| Kowa Pharmaceuticals America, INC. | $116.03 | 2022 | |
| Genzyme Corporation | $112.33 | 2025 | |
| Gilead Sciences, INC. | $107.31 | 2025 | Epclusa |
| Glaxosmithkline, LLC. | $105.60 | 2024 | Arexvy |
| Phathom Pharmaceuticals, INC. | $95.60 | 2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $89.32 | 2023 | Quviviq |
| Amgen INC. | $77.87 | 2025 | Repatha |
| Novartis Pharmaceuticals Corporation | $60.82 | 2023 | |
| Sanofi-Aventis U.S. LLC | $53.60 | 2022 | |
| Exact Sciences Corporation | $37.78 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carolyn Bogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.